← Back to patent-cliff list
NRT-023
Tier C — Watch / tradeNRT-023
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GABA-A receptor; benzodiazepine site
Indications (approved)：Depressive disorder, 产后抑郁症
Regional status
US
Phase II
2024-03-28
EU
-
China
Phase II
2024-07-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NRT-023?
Approved indications include: Depressive disorder, 产后抑郁症.
When does the NRT-023 patent expire?
No public expiry year is available for NRT-023 yet; this page updates once verified.
How do I get a quote for NRT-023 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01